Abivax SA (ABVX) - Total Assets
Based on the latest financial reports, Abivax SA (ABVX) holds total assets worth €652.05 Million EUR (≈ $762.32 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Abivax SA (ABVX) shareholders funds for net asset value and shareholders' equity analysis.
Abivax SA - Total Assets Trend (2013–2024)
This chart illustrates how Abivax SA's total assets have evolved over time, based on quarterly financial data.
Abivax SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Abivax SA's total assets of €652.05 Million consist of 83.2% current assets and 16.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €87.27 Million | 70.3% |
| Accounts Receivable | €15.66 Million | 7.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €2.67 Million | 1.3% |
| Intangible Assets | €6.61 Million | 3.2% |
| Goodwill | €18.42 Million | 9.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Abivax SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ABVX stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abivax SA's current assets represent 83.2% of total assets in 2024, an increase from 14.6% in 2013.
- Cash Position: Cash and equivalents constituted 70.3% of total assets in 2024, up from 7.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 85.0% in 2013.
- Asset Diversification: The largest asset category is cash and equivalents at 70.3% of total assets.
Abivax SA Competitors by Total Assets
Key competitors of Abivax SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Abivax SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.86 | 3.04 | 1.51 |
| Quick Ratio | 7.86 | 3.00 | 1.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €540.53 Million | €163.02 Million | €12.72 Million |
Abivax SA - Advanced Valuation Insights
This section examines the relationship between Abivax SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.43 |
| Latest Market Cap to Assets Ratio | 33.94 |
| Asset Growth Rate (YoY) | -37.3% |
| Total Assets | €205.23 Million |
| Market Capitalization | $6.97 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Abivax SA's assets at a significant premium (33.94x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Abivax SA's assets decreased by 37.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Abivax SA (2013–2024)
The table below shows the annual total assets of Abivax SA from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €205.23 Million ≈ $239.93 Million |
-37.25% |
| 2023-12-31 | €327.06 Million ≈ $382.37 Million |
+345.88% |
| 2022-12-31 | €73.35 Million ≈ $85.76 Million |
-33.54% |
| 2021-12-31 | €110.36 Million ≈ $129.03 Million |
+54.79% |
| 2020-12-31 | €71.30 Million ≈ $83.35 Million |
+37.83% |
| 2019-12-31 | €51.73 Million ≈ $60.48 Million |
-4.29% |
| 2018-12-31 | €54.05 Million ≈ $63.19 Million |
+0.43% |
| 2017-12-31 | €53.81 Million ≈ $62.92 Million |
-11.19% |
| 2016-12-31 | €60.60 Million ≈ $70.84 Million |
-20.55% |
| 2015-12-31 | €76.27 Million ≈ $89.17 Million |
+100.88% |
| 2014-12-31 | €37.97 Million ≈ $44.39 Million |
-1.29% |
| 2013-12-31 | €38.46 Million ≈ $44.97 Million |
-- |
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more